The Psychedelic Executive Order: What You Need to Know

By Steve Elfrink, OmTerra / 3D Healing™ Institute
‍

TL;DR

What happened: On April 18, 2026, Trump signed an executive order to fast-track FDA review of psychedelic medicines for serious mental illness.

‍

How fast: FDA review cut from a year to one or two months. Three classic psychedelic compounds get fast-tracked this week. First approvals possible late 2026 to early 2027.

‍

When you’ll have access: For most people, 2027 to 2028. Veterans and clinical trial participants first. Treatment will be at certified clinics, not retail pharmacies.

‍

What it doesn’t change: Oregon and Colorado state psilocybin programs, religious-use practices, and underground work all remain under existing federal rules.

‍

On April 18, 2026, in the Oval Office, President Trump signed an executive order directing the federal government to accelerate access to psychedelic medicines for serious mental illness. Joe Rogan stood behind him. So did RFK Jr. and former Navy SEAL Marcus Luttrell (of Lone Survivor), alongside FDA and VA leadership and veteran advocates. The order accelerates timelines, directs real money, and creates a fast-track mechanism the field has been trying to build for a decade.

Here is what it actually does, when access becomes real, and what to do if you’re seeking this work.

What the Executive Order Does

The order activates five mechanisms.

FDA Priority Vouchers. The order directs the FDA to issue Commissioner’s National Priority Vouchers (essentially fast-pass tickets that the FDA hands to specific drugs to speed their review) to psychedelic compounds that already hold Breakthrough Therapy designation (an earlier FDA label the agency grants to drugs showing early promise for serious conditions). A drug with one of these vouchers goes through FDA review in one to two months instead of the usual ten to twelve. Eli Lilly’s weight-loss pill Foundayo was approved fifty days after the company submitted its New Drug Application (the formal filing a drug company makes to the FDA to request approval), the fastest such approval since 2002. At the signing, Commissioner Makary announced three classic psychedelic compounds will receive vouchers this coming week.

‍

A New Right-to-Try Pathway for Psychedelics. The order instructs the FDA and DEA to establish a pathway for eligible patients to access investigational psychedelic compounds that are under FDA review and have cleared basic safety thresholds. Ibogaine is named explicitly twice. This is significant because U.S. researchers haven’t been able to run the early human safety trials ibogaine would normally need, since the drug can cause dangerous heart problems. The pathway itself has to be built by FDA and DEA before patients can use it. See the dedicated section below.

‍

$50 Million in Federal Matching Funds. HHS is directed to allocate $50 million through ARPA-H to match state investments in psychedelic research programs. In 2025, Texas passed legislation allocating $50 million in state funds for an ibogaine research consortium, contingent on a $50 million private-sector match for a total program of up to $100 million. No qualifying private partner has been secured; state leaders announced in March 2026 the intent to fully fund the program with state money alone, though implementation remains pending. The federal matching structure in the executive order appears calibrated to encourage similar state programs.

‍

Early DEA Rescheduling Review. Rescheduling normally begins after FDA approval and takes ninety days. The order instructs the Attorney General to begin rescheduling review at the completion of Phase 3 trials, potentially shaving up to three months off the gap between FDA approval and prescription availability. See the dedicated rescheduling section below.

‍

VA / HHS / FDA Data-Sharing. The VA is currently participating in psychedelic clinical trials at nine facilities across multiple states, including California (Loma Linda, Palo Alto, San Diego, San Francisco, Los Angeles), New York (Bronx), Oregon (Portland), Connecticut (West Haven), Nebraska (Omaha), and Vermont (White River Junction). The order requires data-sharing memoranda so VA evidence feeds into FDA review.

What Right to Try Means for Psychedelics

The Right to Try Act is a 2018 federal law, signed by Trump in his first term, that lets seriously ill patients request investigational drugs directly from the manufacturer. The patient and their physician bypass the FDA entirely. The drug must have completed Phase 1 trials (the earliest stage of human safety testing) and remain in active clinical development.

‍

For psychedelics, Right to Try has been largely theoretical. Most psychedelic compounds are Schedule I, which means the DEA treats them as having no accepted medical use. That layers a drug-enforcement problem on top of the access question and has blocked the pathway from operating in practice. The Freedom to Heal Act, introduced in Congress in December 2025, would explicitly extend Right to Try to Schedule I substances that have cleared Phase 1.

‍

The executive order invokes the Right to Try framework and directs the FDA and DEA to build a new pathway for psychedelic access. That pathway does not yet exist operationally. How it will work, which drugs will qualify, and how quickly individual patients can use it are all pending implementation. Ibogaine is named in the order despite not having completed domestic Phase 1 trials, which suggests the administration intends a broader interpretation than the strict Right to Try criteria.

‍

Practical expectation: patients should not plan on Right to Try access being immediately available. The near-term path for seriously ill patients remains clinical trial enrollment.

What Rescheduling Means (and Why It Matters to You)

Under U.S. federal drug law, every controlled substance is placed into one of five “schedules” based on accepted medical use and abuse potential. The schedule a drug sits in determines whether it can be prescribed, how tightly it is regulated, and what penalties apply to unauthorized possession.

‍

Schedule I is the most restrictive category. These substances are defined as having “no currently accepted medical use” and a high potential for abuse. They cannot be prescribed. Examples: heroin, LSD, psilocybin, MDMA, ibogaine, and (currently) marijuana. Every classic psychedelic discussed in the executive order sits in Schedule I today.

‍

Schedule II covers drugs with high abuse potential that also have accepted medical uses. They can be prescribed but are tightly controlled. No refills are allowed; each dispensing requires a new prescription. Examples: morphine, oxycodone, fentanyl, methadone, Adderall, and Ritalin.

‍

Schedule III covers drugs with moderate to lower abuse potential and accepted medical use. Prescriptions can be refilled up to five times within six months and can be called into a pharmacy verbally. Examples: ketamine, testosterone, anabolic steroids, buprenorphine, and Tylenol with codeine.

‍

Schedules IV and V cover substances with progressively lower abuse potential (Xanax, Ambien, and cough syrups with codeine, for example).

Where psychedelics are likely to land: Schedule III. Once the FDA approves a psychedelic medicine, the DEA is required to reschedule it. Legal analysts across the field (Harris Sliwoski’s Psychedelics Law Blog, Harvard’s Petrie-Flom Center, and others) consistently project Schedule III as the most likely landing zone. The pharmacological precedents all point to Schedule III: Spravato (esketamine), Johnson & Johnson’s nasal-spray antidepressant, is Schedule III. Ketamine is Schedule III. Marinol, synthetic THC, is Schedule III.

‍

Only the approved pill, not the mushroom. Here’s a nuance that confuses most coverage: the DEA only reschedules the specific FDA-approved drug product, not the underlying substance. The clearest precedent is cannabis. Marijuana itself stays Schedule I, but the FDA-approved synthetic THC pill Marinol is Schedule III and the CBD-based drug Epidiolex is Schedule V. Expect the same pattern here. If the FDA approves Compass’ synthetic psilocybin drug COMP360, that specific drug gets rescheduled. Psilocybin mushrooms, home-grown or otherwise, stay Schedule I. Same for MDMA: the approved formulation moves, but the substance doesn’t. Same for any LSD product.

‍

What access actually looks like (no, you won’t pick it up at CVS). The closest operating precedent is Spravato, and this is the template to expect. Despite being Schedule III, Spravato is never dispensed at retail pharmacies. It moves through a closed distribution system: specialty pharmacy ships directly to a clinic that has been certified under a REMS program (Risk Evaluation and Mitigation Strategy, an FDA safety framework that controls how high-risk drugs are distributed and administered), where the patient receives it under direct observation, is monitored for at least two hours, and never takes the drug home. Patients do not carry prescriptions to Walgreens. They visit a certified clinic where the medicine is administered, monitored, and documented. Expect psilocybin and MDMA, if approved, to operate under essentially identical rules. The Schedule III classification matters for DEA enforcement, tax treatment, and legal status, but the patient experience will look like a clinic-based treatment, not a pharmacy refill.

‍

What rescheduling doesn’t change. Because rescheduling is formulation-specific, nothing outside the approved drug product moves. Oregon and Colorado state psilocybin service centers, which use non-FDA-approved psilocybin, continue operating under Schedule I federal law. Ayahuasca ceremonies, home-grown mushrooms, underground practitioners, and every other non-pharmaceutical form of these medicines stay where they are federally. Rescheduling does not legalize recreational use, does not decriminalize possession outside a valid clinical pathway, and does not reach the broader plant-medicine landscape.

The Timelines

This week (late April 2026). Three priority vouchers are issued to three classic psychedelic compounds. The FDA has not named them. Based on public pipeline data, the likely candidates are Compass Pathways’ COMP360 (synthetic psilocybin for treatment-resistant depression, positive Phase 3 data February 2026, New Drug Application targeted for late 2026); Cybin’s CYB003 (a psilocybin-based compound in Phase 3 for major depressive disorder); and Definium Therapeutics’ DT120 (formerly MindMed, an LSD-based compound with Phase 3 data readouts beginning in April to June 2026). Commissioner Makary specified these three would be classic psychedelics (compounds that act on the same brain receptors as psilocybin and LSD), which means MDMA is excluded from this batch. Ketamine-based drugs like Spravato are also excluded because they work on a different receptor system. These are informed guesses; the FDA is expected to announce the actual recipients in the coming days.

‍

Summer 2026. Commissioner Makary stated publicly that FDA decisions could be expected “later this summer.” Given that Compass Pathways is not targeting its New Drug Application submission until late 2026, summer approvals would have to come from applications not yet publicly identified or from programs moving faster than their stated timelines.

‍

Late 2026 to early 2027. The most realistic window for first FDA approval of a classic psychedelic. Compass Pathways has stated it aims to be “launch-ready by the end of 2026.” DEA rescheduling normally follows approval within ninety days; with the order’s instruction that rescheduling review begin at Phase 3 completion, that lag can be partially pre-consumed.

‍

2027 and 2028. The rest of the pipeline catches up. Definium has multiple Phase 3 LSD readouts scheduled in 2026 with potential FDA submissions following. Cybin, Atai subsidiaries, and other developers are further back but moving. Ibogaine domestic trials still have to clear basic cardiac safety hurdles. The Texas Ibogaine Research Consortium (IMPACT) led by UTHealth Houston and UTMB was announced in December 2025, with Phase 1 trials still to come, pointing to 2028 at earliest for approval-track data.
‍

What the Access Model Will Look Like

The federal model is pharmaceutical, medicalized, and clinic-based. Approved psychedelics will almost certainly operate under a closed distribution system modeled on Spravato (esketamine): specialty pharmacy to certified clinic, administered under direct observation, monitored for two or more hours, never dispensed for home use. Even once rescheduled to Schedule III, the approved products will not be available at retail pharmacies. Patients will visit certified clinics to receive treatment.

‍

Expected rollout order based on current pipeline data:

1. Psilocybin (Compass Pathways COMP360). For treatment-resistant depression. Two positive Phase 3 trials. FDA application targeted for late 2026.

2. Psilocybin-based compound (Cybin CYB003). In Phase 3 trials for major depressive disorder. Breakthrough Therapy designation.

3. LSD (Definium Therapeutics DT120). Formerly MindMed. For generalized anxiety disorder and major depressive disorder. Three Phase 3 results expected through 2026.

4. MDMA (Resilient Pharmaceuticals). Formerly Lykos. FDA asked for a new Phase 3 trial after the 2024 rejection, delaying the timeline significantly. MDMA is not among the three classic psychedelics receiving vouchers this week.

5. Ibogaine. Longer horizon. Cardiac safety remains the central concern, though a 2024 Stanford study in veterans with traumatic brain injury demonstrated that pairing ibogaine with magnesium substantially reduces cardiac risk. The magnesium co-administration protocol is becoming standard in research settings. The Texas IMPACT consortium and federal matching funds are accelerating research, but an approval-track trial is likely years away.

‍

Insurance coverage is the next major open question. If the full treatment (preparation, dosing sessions, and integration) costs $8,000 to $15,000 and isn’t reimbursed, access will skew toward patients who can pay out of pocket.
‍

Who Gets Access First

Veterans. The order places veterans at the front of the line through VA trial participation, the data-sharing memoranda, and the ibogaine provisions. Veteran advocacy (Rogan, the Luttrell brothers, Americans for Ibogaine) drove this moment. Veterans with serious mental illness, PTSD, or TBI will have the cleanest path.

‍

Clinical trial participants. ClinicalTrials.gov is the database. VA trials are running at nine facilities across at least six states. Industry-sponsored trials are active nationwide. Trial participation remains the fastest and most supported path.

‍

Patients with serious conditions who have exhausted standard treatments. As the FDA and DEA build the Right to Try pathway the order requires, these patients may become eligible for investigational access through manufacturer petitions. Timing and mechanics depend on implementation.

‍

The general public. Approval, rescheduling, REMS setup, clinician training, and clinic buildout together point to 2027 for the earliest realistic clinic-based access, and 2028 before access is broad enough to matter at population scale.
‍

What the Order Doesn’t Cover

Religious use. Ayahuasca churches, peyote practitioners outside the Native American Church (which has its own separate federal protections), and other spiritually-oriented psychedelic communities remain under existing DEA posture. The order is silent on their status.

‍

State programs. Oregon’s Measure 109 psilocybin service centers and Colorado’s Proposition 122 facilitated-use framework operate under state authority. The order neither expands nor protects them. State programs remain exposed to the same federal enforcement posture they faced before.

‍

Underground practitioners. The order’s model assumes FDA-approved products delivered in clinical settings. Community and underground practice gain nothing here.

‍

Therapy standards. The order accelerates drug review but does not establish standards for therapist training, preparation protocols, monitoring ratios, or integration infrastructure. The 2024 Lykos MDMA rejection was substantially about trial-container issues (blinding, protocol consistency, clinician conduct). Those questions remain open.
‍

A Note on the Rollout

The clinical work surrounding a psychedelic session (screening, preparation, session support, and integration) does as much to shape outcomes as the medicine itself. As approvals arrive and access expands nationwide, the field will need to build out robust screening and integration infrastructure to match the scale. The guiding principles are the same ones that apply to any new medicine coming to market. Do no harm. Improve efficacy. Minimize risk.

‍

One practical constraint worth naming: a psilocybin or MDMA session runs six to eight hours, compared to the roughly two hours of monitoring required for Spravato. That difference has real implications for clinic infrastructure and for the clinician workforce. The number of trained providers qualified to deliver these therapies is currently small relative to the patient demand approval will generate. Expect the training pipeline to become a near-term bottleneck even as the drugs themselves become available.
‍

If You’re Seeking Access: Your Options

1. If you are a veteran, contact your VA clinic about current psychedelic trial participation. Nine VA facilities across the country are actively participating in studies.

2. If you meet diagnostic criteria but are not a veteran, search ClinicalTrials.gov for Compass Pathways, Cybin, Definium Therapeutics, and Resilient Pharmaceuticals studies. Trial participation is the fastest supported path. Be aware that commercial trials often exclude patients with active suicidality, recent substance use, or certain comorbidities, so eligibility isn’t universal.

3. If you want psychedelic-adjacent treatment now, ketamine is the only FDA-legal option widely available today. Spravato (esketamine nasal spray) is FDA-approved for treatment-resistant depression and delivered in the same kind of certified clinic model psychedelics will use. Off-label intramuscular and IV ketamine clinics operate nationwide. Neither is a psychedelic in the classic sense, but both are the near-term reality while the rest of the field catches up.

4. If you are seriously ill and have exhausted standard treatments, watch for the Right to Try pathway the order directs FDA and DEA to build. Timing depends on regulatory implementation. In the meantime, clinical trial enrollment remains the most reliable access route.

5. If you live in Oregon or Colorado, state-level psilocybin service centers are already operational. For people with treatment-resistant conditions who can travel, these are currently the single fastest legal path to supervised psilocybin in the United States. They operate under state authority, not federal, so eligibility and cost structures differ from what FDA-approved access will look like.

6. Regardless of pathway, work with a qualified clinician experienced in psychedelic-assisted therapy. Ask about preparation, session support, and integration before you begin.

7. Don’t wait for approval. Even on compressed timelines, most patients won’t have clinic-based access for eighteen to thirty-six months. Preparatory work can begin now.
‍

Bottom Line

The order accelerates FDA review of psychedelic medicines, directs FDA and DEA to build a new Right to Try pathway for investigational access, and puts veterans at the front of the line. The first FDA approval is realistic in late 2026 or early 2027, with most patients likely to see access in 2027 to 2028. Approved psychedelics will almost certainly be rescheduled to Schedule III (following the Spravato precedent) and delivered through a closed clinic-based distribution system, not retail pharmacies. State programs, religious practice, and underground work continue under their existing legal regimes.

‍

If you’re looking for this work, the most useful things you can do now are understand your access pathway, find a qualified clinician, and keep an eye on the implementation details the executive order sets in motion.

‍

Steve Elfrink is a psychedelic and psycholytic somatic therapist, founder of OmTerra and the 3D Healing™ Institute, and co-author of peer-reviewed publications on Psychedelic Iatrogenic Structural Dissociation (Frontiers in Psychology, 2025) and Psychedelic Somatic Interactional Psychotherapy. (Journal of Psychedelic Psychiatry 2020) He practices in Southern Oregon. omterra.org

‍